Companion Diagnostics: Technologies and Markets

Companion Diagnostics: Technologies and Markets

Report Scope

The current report provides detailed coverage of the companion diagnostics market. This report highlights the current and future market potential of companion diagnostics, and it includes a detailed analysis of the drivers, opportunities, restraints, and challenges in the market. The report details the companion diagnostics market share based on product and service, type of test, technology, and application. The market’s products and services is segmented into instruments, consumables, and services. It is categorized based on the type of test into commercial CDx and lab-developed tests (LDT)-CDx. Based on technology, the market is segmented into polymerase chain reaction, immunohistochemistry, next-generation sequencing, in situ hybridization, genotyping, immunoassays, exosomes, others, and services market. Based on application, the CDx market is categorized into cancer, neurologic disorders, cardiovascular disease, infectious disease, and others. Based on end users, the companion diagnostics market is segmented into clinical laboratories, pharmaceutical companies, contract research organizations (CROs), and other end users. The report also includes company profiles of the major players in the companion diagnostics market, with details about each company's business segments, financials, product portfolios, and recent developments.

By geographical region, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The North America region includes the U.S. and Canada; Europe includes Germany, the U.K., Italy, France, and the Rest of Europe; Asia-Pacific includes China, India, Japan, and the Rest of Asia-Pacific. For market estimates, data has been provided for 2020 and 2021 as the historic years, 2022 as the base year, and 2028 as the forecast year.

Report Includes

54 data tables and 59 additional tables

Overview and an analysis of the global markets for companion diagnostics (CDx).

Analyses of the global market trends, with historical market revenue data (sales figures) from 2021 to 2022, estimates for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028.

A look at the current and future market potential of companion diagnostics along with the market dynamics, competitive landscape and regulatory scenario.

Estimate of the market size and revenue forecast for the global CDx market, and corresponding market share analysis based on product and services, test type, technology, application, end user and region.

Discussion of the market opportunities for CDx products by identification of high-growth applications in different therapeutic areas, with a focus on the largest and fastest-expanding markets for diseases.

Analysis of recent market developments and clinical trials, as well as the leading companies engaged in R&D and product developments in CDx reagents.

Discussion of the importance of ESG in the CDx industry, including consumer attitudes, the impact of ESG on company performance, ESG score analysis, and ESG practices followed by leading companies.

Review of key patent grants and patent applications related to CDx.

Identification of the major vendors along with an analysis of the competitive intelligence, including companies’ market shares, recent M&A activity, and venture funding outlook.

Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Agilent Technologies Inc., and QIAGEN

Companies Mentioned

ABBOTT
AGILENT TECHNOLOGIES INC.
ARUP LABORATORIES
BIOMERIEUX
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
ILLUMINA INC.
MYRIAD GENETICS INC.
QIAGEN
THERMO FISHER SCIENTIFIC INC.